Thrombin inhibitors. A new generation of antithrombotics

Trends in Cardiovascular Medicine

Volumn 5, Issue 4, 1995, Pages 134-140

  Stone, Stuart R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRUDIN; HIRULOG; THROMBIN; THROMBIN INHIBITOR;

CORONARY ARTERY DILATATION; DRUG RESEARCH; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0029122633     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/1050-1738(95)00049-F     Document Type: Short Survey

References (44)

1. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
2. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models
3. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-Me-Phe-Pro-Arg-H
4. Binding of thrombin to subendothelial extracellular matrix protection and expression of functional properties
5. Selection of single-stranded DNA molecules that bind and inhibit human thrombin
6. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and the significance of the Tyr-Pro-Pro-Trp insertion segment
7. Refined 2.3 Å x-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA: a starting point for improving antithrombotics
8. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial
9. Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position
10. Thrombin receptor function and cardiovascular disease
11. The coagulation cascade: interaction, maintenance and regulation
12. The protein C anticoagulant pathway
13. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
14. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
15. New antithrombotic strategies for resistant thrombotic processes
16. Low molecular weight heparins
17. Electrostatic interactions in the association of proteins: an analysis of the thrombin-hirudin complex
18. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin
19. 2Cl: a selective affinity label for thrombin
20. The selective inhibition of thrombin by peptides of boroarginine
21. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)-sulfonyl]-L-arginyl]-2-piperidinecarboxylic acid
22. In vivo characterization of a new synthetic thrombin inhibitor
23. Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin
24. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
25. ™, in unstable angina: anticoagulant, antithrombotic, and clinical effects
26. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
27. 2Cl in baboons
28. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin
29. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes
30. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805)
31. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study
32. The structure of α-thrombin inhibited by a 15-mer single-stranded DNA aptamer
33. Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors
34. The structure of a complex of recombinant hirudin and human α-thrombin
35. Structure of the hirugen and hirulog 1 complexes of α-thrombin
36. A player of many parts: the spotlight falls on thrombin's structure
37. Inhibition of bovine and human thrombins by derivatives of benzamidine
38. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile
39. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor
40. ™, in place of heparin during coronary angioplasty
41. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial
42. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty
43. New anticoagulant strategies
44. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors